[ad_1]
Osaka – Japanese pharmaceutical agency Shionogi & Co. stated Wednesday its oral COVID-19 drug presently beneath improvement has been confirmed in preclinical testing to be efficient in opposition to the omicron subvariant BA.2.75, which has been detected in Japan.
The announcement got here after a well being ministry panel in July postponed the granting of emergency approval for the drug. Discussions are slated to renew after the outcomes of the ultimate stage of medical trials presently underway.
In a time of each misinformation and an excessive amount of data, high quality journalism is extra essential than ever.
By subscribing, you possibly can assist us get the story proper.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
[ad_2]
Source link
